Atengen, Inc. Information

Atengen’s novel therapeutic target is expressed specifically in tumor blood vessels of most types of solid tumors but not in the blood vessels of healthy organs. Our scientists have used innovative technologies to identify several drug candidates that not only suppress tumor growth by inhibiting new blood vessel growth, but also cause extensive tumor necrosis by killing existing tumor blood vessels. In targeting the tumor blood supply rather than the tumor cells themselves, we can kill solid tumors in a tissue agnostic manner, while still maintaining a high degree of specificity. This groundbreaking approach has the potential to revolutionize the treatment of solid tumors.